TP53 mutations are associated with CD19− relapse and inferior outcomes after blinatumomab in adults with ALL

Abstract: Despite the success of the CD19 × CD3 T-cell engager blinatumomab in B-cell acute lymphoblastic leukemia (B-ALL), treatment failure is common and can manifest with antigen loss and extramedullary disease (EMD) relapse. To understand the impact of leukemia genetics on outcomes, we reviewed...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Ibrahim Aldoss, Shanpeng Li, Jianying Zhang, Mary C. Clark, Vaibhav Agrawal, Hoda Pourhassan, Paul Koller, Ahmed Aribi, Haris Ali, Amanda Blackmon, Salman Otoukesh, Karamjeet Sandhu, Brian Ball, Shukaib Arslan, Andrew Artz, Idoroenyi Amanam, Monzr M. Al Malki, Amandeep Salhotra, Tibor Kovacsovics, Lindsey Murphy, Michelle Afkhami, Dat Ngo, Jose Tinajero, Zhaohui Gu, Pamela S. Becker, Ryotaro Nakamura, Anthony Stein, Guido Marcucci, Stephen J. Forman, Vinod Pullarkat
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Elsevier 2025-05-01
Ráidu:	Blood Advances
Liŋkkat:	http://www.sciencedirect.com/science/article/pii/S2473952925000333
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!